Evidence map›Paper›PMID 41997152›Full record

ArticleStem cell reports2026

An optimized protocol for efficient derivation of pancreatic islets from multiple human pluripotent stem cell lines.

Siqin Wu, Shivam Chandel, Galyna Bryzgalova, Paschalis Efstathopoulos, Kelly Blust, Cheng Zhao, Eda Erbil, Anna Falk, My Hedhammar, Per-Olof Berggren and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Siqin WuDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden; Gynecology and Reproductive Medicine, Karolinska Universitetssjukhuset, 141 86 Stockholm, Sweden; Spiber Technologies AB, AlbaNova University Center, 106 91 Stockholm, Sweden. Electronic address: siqinw@gmail.com.
Shivam ChandelDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden; Gynecology and Reproductive Medicine, Karolinska Universitetssjukhuset, 141 86 Stockholm, Sweden.
Galyna BryzgalovaThe Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, 171 76 Stockholm, Sweden.
Paschalis EfstathopoulosDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden; Gynecology and Reproductive Medicine, Karolinska Universitetssjukhuset, 141 86 Stockholm, Sweden; Spiber Technologies AB, AlbaNova University Center, 106 91 Stockholm, Sweden.
Kelly BlustDivision of Protein Technology, KTH Royal Institute of Technology, Roslagstullsbacken 21, 106 91 Stockholm, Sweden.
Cheng ZhaoDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden; Gynecology and Reproductive Medicine, Karolinska Universitetssjukhuset, 141 86 Stockholm, Sweden.
Eda ErbilDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden; Gynecology and Reproductive Medicine, Karolinska Universitetssjukhuset, 141 86 Stockholm, Sweden.
Anna FalkDepartment of Neuroscience, Karolinska Institutet, 171 65 Solna, Sweden; Neural Stem Cells, Department of Experimental Medical Science, Lund Stem Cell Center, Lund University, 221 84 Lund, Sweden.
My HedhammarDivision of Protein Technology, KTH Royal Institute of Technology, Roslagstullsbacken 21, 106 91 Stockholm, Sweden.
Per-Olof BerggrenThe Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, 171 76 Stockholm, Sweden. Electronic address: per-olof.berggren@ki.se.
Fredrik LannerDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden; Gynecology and Reproductive Medicine, Karolinska Universitetssjukhuset, 141 86 Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The success of cell therapy for type 1 diabetes (T1D) depends on reliable differentiation of stem cells into functional pancreatic islets. Current protocols produce stem cell-derived islets (SC-islets) that contain non-endocrine cells and show limited maturity. We developed a robust protocol that generates functional SC-islets from all eight tested human pluripotent stem cell (hPSC) lines. Differentiation to the endocrine progenitor (EP) stage on 2D laminin-521 is improved by shortening the prior pancreatic progenitor (PP) stage. Notably, allowing EP cells to self-aggregate efficiently removes proliferative and non-endocrine cells. Subsequent suspension culture yields SC-islets with strong glucose responsiveness in vitro. After transplantation into the anterior chamber of the eye of diabetic mice, SC-islets further mature and restore normal glycemic control. Single-cell analyses show that the SC-islets are free of non-endocrine cell populations before and after transplantation. This protocol enables production of highly functional SC-islets suitable for T1D cell therapy.

Indexed as

Cell Culture TechniquesCell DifferentiationIslets of LangerhansPluripotent Stem CellsAnimalsCell LineDiabetes Mellitus, ExperimentalHumansIslets of Langerhans TransplantationMicebeta cellscell-line variabilitycell therapydiabetesdifferentiation protocolendocrine progenitorsendocrine purityfunctional SC-isletshuman pluripotent stem cellsintraocular transplantation

Identifiers

PMID41997152
PMCPMC13163220

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.